Significance of epithelial membrane antigen in the work‐up of problematic serous effusions

Differentiation of reactive and/or atypical mesothelial cells from malignant epithelial cells in serous effusions remains a frequent diagnostic problem. Since epithelial membrane antigen (EMA) positive malignant cells in serous effusions have been reported in almost all adenocarcinomas and most malignant mesotheliomas, immunoreactivity for EMA is felt to be less useful than other antibodies in the workup of problematic serous effusions. However, immunostaining of reactive and/or atypical benign mesothelial cells for EMA has not been well studied, with only a few series reporting either weak or negative staining for EMA. This study was undertaken to evaluate how often reactive and/or atypical appearing mesothelial cells stain positively for EMA. One hundred eighty serous effusions (115 pleural, 55 peritoneal, and 10 pericardial) from 123 females and 57 males ages 20 to 89 yr were evaluated in which an antibody panel including EMA was performed on cell blocks (141 cases), cytospins (36 cases), or both (3 cases). Of the 100 cytologically positive cases, EMA immunoreactivity was present in 97/100 (97%) cases. One EMA negative case suspicious for a metastatic renal cell carcinoma was lost to follow‐up and not included in the analysis. The remaining three negative cases consisted of malignancies not expected to have EMA positive cells (small cell carcinoma, neuroblastoma, and synovial sarcoma). Therefore, EMA was positive in virtually 100% of the remaining malignant cases. In the 78 cytologically negative cases, EMA positivity was present in 3/78 (3.8%) cases. Clinical follow‐up of up to 14 mo in these three cases revealed no evidence of malignancy. One cytologically negative case with EMA positive cells was lost to follow‐up and therefore not included in the analysis. This study demonstrates that only a low percentage of cytologically negative serous effusions will have EMA positive reactive and/or atypical mesothelial cells. Although not discriminatory between adenocarcinoma and malignant mesothelioma, EMA is a useful antibody for separating reactive and/or atypical mesothelial cells from malignant epithelial and mesothelial cells and should be included as part of an antibody panel in the workup of problematic effusions. © 1995 Wiley‐Liss, Inc.

[1]  L. Weiss,et al.  The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. , 1993, Human pathology.

[2]  W. Mccarthy,et al.  Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[3]  J. Silverman,et al.  Immunocytochemical panel for the identification of malignant cells in serous effusions. , 1991, American journal of clinical pathology.

[4]  H. Battifora,et al.  Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis. , 1990, American journal of clinical pathology.

[5]  C. Cohen,et al.  Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. , 1990, Acta cytologica.

[6]  S. Mills,et al.  Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. , 1990, Human pathology.

[7]  P. Carder,et al.  Monoclonal antibodies in the cytodiagnosis of serous effusions , 1990, Cytopathology : official journal of the British Society for Clinical Cytology.

[8]  A. Leong,et al.  “Thick” cell membranes revealed by immunocytochemical staining: A clue to the diagnosis of mesothelioma , 1990, Diagnostic cytopathology.

[9]  N. Ordóñez.  The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma , 1989, The American journal of surgical pathology.

[10]  C. Herman,et al.  Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[11]  T. H. van der Kwast,et al.  Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study. , 1988, Acta cytologica.

[12]  C. Bedrossian,et al.  Value of immunocytochemistry in the study of malignant effusions , 1987, Diagnostic cytopathology.

[13]  P. Thomas,et al.  Keratins versus epithelial membrane antigen in tumor diagnosis: an immunohistochemical comparison of five monoclonal antibodies. , 1987, Human pathology.

[14]  J. Silverman,et al.  The use of immunoperoxidase panels for the cytologic diagnosis of malignancy in serous effusions , 1987, Diagnostic cytopathology.

[15]  C. Otis,et al.  Immunohistochemical Evaluation of Pleural Mesothelioma and Pulmonary Adenocarcinoma: A Bi-institutional Study of 47 Cases , 1987, The American journal of surgical pathology.

[16]  J. Said,et al.  Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: Immunocytochemical and ultrastructural localization in benign and malignant cells , 1987, Diagnostic cytopathology.

[17]  K. Gatter,et al.  Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. , 1987, Journal of clinical pathology.

[18]  E. Cibas,et al.  The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. , 1987, Human pathology.

[19]  G. Pinkus,et al.  Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal and polyclonal antibodies. , 1986, American journal of clinical pathology.

[20]  M. McNutt,et al.  Reactive and Neoplastic Serosal Tissue: A Light-Microscopic, Ultrastructural, and Immunocytochemical Study , 1986, The American journal of surgical pathology.

[21]  D. Mason,et al.  A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2. , 1985, British Journal of Cancer.

[22]  L. Kobzik,et al.  The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy. , 1985, Acta cytologica.

[23]  H. Battifora,et al.  Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach , 1985, Cancer.

[24]  J. Taylor‐Papadimitriou,et al.  Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. , 1983, Journal of clinical pathology.

[25]  Walts Ae,et al.  Specific tumor markers in diagnostic cytology. Immunoperoxidase studies of carcinoembryonic antigen, lysozyme and other tissue antigens in effusions, washes and aspirates. , 1983 .

[26]  J. Said,et al.  Keratin proteins and carcinoembryonic antigen in lung carcinoma: an immunoperoxidase study of fifty-four cases, with ultrastructural correlations. , 1983, Human pathology.

[27]  D. Coleman,et al.  Epithelial Membrane Antigen. Its use in the cytodiagnosis of malignancy in serous effusions. , 1982, American journal of clinical pathology.

[28]  A. Neville,et al.  Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions. , 1981, Journal of clinical pathology.

[29]  J. Sloane,et al.  Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology , 1981, Cancer.